FIELD: chemistry.
SUBSTANCE: invention describes novel azabiphenylaminobenzoic acid derivatives, having the chemical formula: 
, where R1 is selected from a group consisting of hydrogen atoms, halogen atoms, C1-4-alkyl, C3-4-cycloalkyl and -CF3, R2 is selected from a group consisting of hydrogen atoms, halogen atoms and C1-4-alkyl group, R3 is -COOR5, where R5 is selected from a group consisting of a hydrogen atom and linear or branched C1-4-alkyl groups, R4 is selected from a group consisting of a hydrogen atom and C1-4-alkyl group; R9 is selected from a group consisting of a hydrogen atom and a phenyl group, G1 is a group selected from N and CR6, where R6 is selected from a group consisting of hydrogen atoms, halogen atoms, C1-4-alkyl, C3-4-cycloalkyl, -CP3 and C6-10-aryl group, G2 is a group selected from: - a hydrogen atom, hydroxy group, halogen atom, C3-4-cycloalkyl group, C1-4-alkoxy group and -NRaRb, where Ra is C1-4-alkyl group and Rb is selected from a group consisting of C1-4-alkyl group and C1-4-alkoxy-C1-4-alkyl group, or Ra and Rb together with the nitrogen atom with which they are bonded, form a saturated 6-8-member heterocyclic ring optionally containing one oxygen atom as an additional heteroatom, -monocyclic or bicyclic 5-10-member heteroatomatic ring containing one or more nitrogen atoms which are optionally substituted with one or more halogen atoms, and a phenyl group which is optionally substituted with one or more substitutes selected from halogen atoms, C1-4-alkyl, hydroxy group, C1-4-alkoxy group, C3-4-cycloalkyl, C3-4-cycloalkoxy group, cyano group, -CF3, -OCF3, -CONR7R8, oxadiazolyl, and where R7 and R8 are independently selected from a hydrogen atom, a linear or branched C1-4-alkyl group, C3-7-cycloalkyl group, or R7 and R8 together with a nitrogen atom with which they are bonded form a group of formula: 
, where n equals 0-3; or G2 together with R6 form a non-aromatic C5-10-carbocyclic group or a C6-10-aryl group, and pharmaceutically acceptable and N oxides thereof. Also described are pharmaceutical compositions containing said compounds and use thereof in treatment as dehydroorotate dehydrogenase (DHODH) inhibitors.
EFFECT: novel compounds which can be used as dehydroorotate dehydrogenase inhibitors are obtained and described.
30 cl, 118 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW DERIVATIVES OF PYRIDAZIN-3(2H)-ONE | 2003 |
|
RU2346939C2 |
| DERIVATIVES OF PYRIDINE AND PYRIMIDINE, METHODS FOR THEIR PREPARING (VARIANTS), PHARMACEUTICAL COMPOSITION AND USING | 2003 |
|
RU2293731C2 |
| 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | 2008 |
|
RU2481333C2 |
| COMPOUNDS AND COMPOSITIONS AS CANNABINOID RECEPTOR 1 INHIBITORS | 2005 |
|
RU2431635C2 |
| DERIVATIVES OF HYDRAZONE-PYRAOLE AND MEDICAL APPLICATION THEIROF | 2002 |
|
RU2332996C2 |
| [1,2,4]OXADIAZOLES (VERSIONS), METHODS OF OBTAINING THEM, PHARMACEUTICAL COMPOSITION AND METHOD OF INHIBITING ACTIVATION OF METABOTROPIC GLUTAMATE RECEPTORS - 5 | 2003 |
|
RU2352568C9 |
| SERINE/THREONINE KINASE INHIBITORS | 2013 |
|
RU2650501C2 |
| PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | 2007 |
|
RU2485115C2 |
| SUBSTITUTED BENZO[d]ISOXAZOL-3-YLAMINE COMPOUNDS AND USE THEREOF AS ANALGESICS | 2006 |
|
RU2416607C2 |
| NEW IMIDE DERIVATIVES AND THEIR USE AS DRUG | 2016 |
|
RU2772429C2 |
